SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Natco Pharma informs about analyst meet

16 Nov 2023 Evaluate
Pursuant to Regulation 30 & 46 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and further to intimation letter dated 9th November, 2023, Natco Pharma has informed that the audio recording of the earnings call for the quarter and half year ended 30th September 2023, held on 15th November, 2023 at 11.00 Hrs IST have been uploaded on website at the following weblink: https://www.natcopharma.co.in/wp-content/uploads/2023/11/Q2FY24earningscall.mp3

The above information is a part of company’s filings submitted to BSE.

Natco Pharma Share Price

1208.75 34.75 (2.96%)
11-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1872.40
Dr. Reddys Lab 1279.70
Cipla 1304.70
Zydus Lifesciences 956.65
Lupin 2245.65
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×